Armata Pharmaceuticals, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
ARMP$3.75-1.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Deficit
Three Months Ended March 31, 2026 and 2025
(in thousands, except share data)
| | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| · · Stockholders’ Deficit | ||||||||||||||
| · · Common Stock · · · · · · · · · | ||||||||||||||
| · · · · · · · Additional · · · · Total | ||||||||||||||
| · · · · · · · Paid-in · · Accumulated · · Stockholders’ | ||||||||||||||
| · · Shares · · Amount · · Capital · · Deficit · · Deficit | ||||||||||||||
| Balances, December 31, 2024 | 36,183,067 | | $362 | | $279,354 | | $(327,735) | | $(48,019) | |||||
| Issuance of Common Stock upon release of restricted stock units, net of tax withholdings | | 10,412 | | | — | | | (14) | | | — | | | (14) |
| Stock-based compensation expense | — | | | — | | | 781 | | | — | | 781 | ||
| Net loss | — | | | — | | | — | | | (6,531) | | (6,531) | ||
| Balances, March 31, 2025 | 36,193,479 | | $362 | | $280,121 | | $(334,266) | | $(53,783) | |||||
| | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | |
| | | Stockholders’ Deficit | ||||||||||||
| | | Common Stock | | | | | | | | | | |||
| | | | | | | | Additional | | | | Total | |||
| | | | | | | | Paid-in | | Accumulated | | Stockholders’ | |||
| | | Shares | | Amount | | Capital | | Deficit | | Deficit | ||||
| Balances, December 31, 2025 | 36,431,444 | | $364 | | $282,574 | | $(501,534) | | $(218,596) | |||||
| 2026 Debt and Warrant Amendments (Note 8) | | — | | | — | | | 20,640 | | | — | | | 20,640 |
| Exercise of stock options | | 201,708 | | | 2 | | | 702 | | | — | | | 704 |
| Issuance of Common Stock upon release of restricted stock units, net of tax withholdings | | 11,551 | | | — | | | (63) | | | | | | (63) |
| Stock-based compensation expense | | — | | | — | | | 1,075 | | | — | | | 1,075 |
| Net loss | — | | | — | | | — | | | (115,346) | | | (115,346) | |
| Balances, March 31, 2026 | 36,644,703 | | $366 | | $304,928 | | $(616,880) | | $(311,586) | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.